Jefferies starts Verastem at Buy

|About: Verastem (VSTM)|By:, SA News Editor

Verastem (VSTM +1.7%) is initiated with a Buy rating at Jefferies. Price target is $21, representing a 42% upside from Friday's close.

Analyst Biren Amin says VS-6063 "has favorable odds of showing a PFS benefit [in mesothelioma trials], supporting potential accelerated approval in H2 2016."

 For more on VS-6063, see previous coverage.